En bisemanal se encuentra sobre una zona de fluctuacion de precios antigua. Está consolidando el fortísimo movimiento al alza previo sobre la caja. Cabe un retesteo, pero tambien es posible que salga por arriba y pueda pegarse un buen run.
No es apta para aficionados. Pura especulación.
| Business Summary |
|---|
Provectus
Biopharmaceuticals, Inc., a development-stage pharmaceutical company,
engages in developing pharmaceuticals for oncology and dermatology
indications. The company’s product line includes PV-10, a Phase II study
completed drug candidate for metastatic melanoma, a Phase I study
completed candidate for breast cancer, and a Phase I protocol expansion
candidate for liver metastasis; and PH-10, a Phase IIc randomized study
initiated drug candidate for the treatment of psoriasis, and Phase II
study completed candidate for atopic dermatitis. It also develops PH-10
for the treatment of actinic keratosis and severe acne vulgaris. In
addition, the company develops over-the-counter pharmaceuticals,
including GloveAid, a hand cream with antiperspirant and antibacterial
properties; Pure-ific line of products to prevent the spread of germs on
skin; and Pure-Stick and Pure N Clear acne products. Further, it
develops medical device technologies for markets comprising cosmetic
treatments, such as reduction of wrinkles and elimination of spider
veins, and other cosmetic blemishes; and therapeutic uses, including
photoactivation of PH-10 other prescription drugs and non-surgical
destruction of certain skin cancers. The company was formerly known as
Provectus Pharmaceuticals, Inc. and changed its name to Provectus
Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals,
Inc. was founded in 2002 and is based in Knoxville, Tennessee.